Patents by Inventor Gene Jamieson
Gene Jamieson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8716279Abstract: The present invention includes benzodiazepine compositions formulated for intranasal administration, comprising a binary solvent system comprising a first solvent in which the benzodiazepine is soluble, the first solvent capable of penetrating nasal mucosal tissue, and a second solvent in which the benzodiazepine in less soluble. The compositions of the present invention may be used to treat a variety of disorders including, but not limited to, panic attacks, muscle spasms, anxiety, and seizures. In one aspect, the present invention relates to a fast-acting, clonazepam composition for transnasal administration that can be used for the treatment of seizure clusters.Type: GrantFiled: August 27, 2007Date of Patent: May 6, 2014Assignee: Jazz Pharmaceuticals, Inc.Inventors: Gene Jamieson, Michael Des Jardin, Clark Allphin, Sigridur Olafsdottir
-
Patent number: 8609651Abstract: The present invention includes benzodiazepine compositions formulated for intranasal administration, comprising a binary solvent system comprising a first solvent in which the benzodiazepine is soluble, the first solvent capable of penetrating nasal mucosal tissue, and a second solvent in which the benzodiazepine in less soluble. The compositions of the present invention may be used to treat a variety of disorders including, but not limited to, panic attacks, muscle spasms, anxiety, and seizures. In one aspect, the present invention relates to a fast-acting, clonazepam composition for transnasal administration that can be used for the treatment of seizure clusters.Type: GrantFiled: August 27, 2007Date of Patent: December 17, 2013Assignee: Jazz Pharmaceuticals, Inc.Inventors: Gene Jamieson, Michael Des Jardin, Clark Allphin, Sigridur Olafsdottir
-
Publication number: 20080076761Abstract: The present invention includes benzodiazepine compositions formulated for intranasal administration, comprising a binary solvent system comprising a first solvent in which the benzodiazepine is soluble, the first solvent capable of penetrating nasal mucosal tissue, and a second solvent in which the benzodiazepine in less soluble. The compositions of the present invention may be used to treat a variety of disorders including, but not limited to, panic attacks, muscle spasms, anxiety, and seizures. In one aspect, the present invention relates to a fast-acting, clonazepam composition for transnasal administration that can be used for the treatment of seizure clusters.Type: ApplicationFiled: August 27, 2007Publication date: March 27, 2008Applicant: Jazz PharmaceuticalsInventors: Gene Jamieson, Michael Des Jardin, Clark Allphin
-
Publication number: 20080070904Abstract: The present invention includes benzodiazepine compositions formulated for intranasal administration, comprising a binary solvent system comprising a first solvent in which the benzodiazepine is soluble, the first solvent capable of penetrating nasal mucosal tissue, and a second solvent in which the benzodiazepine in less soluble. The compositions of the present invention may be used to treat a variety of disorders including, but not limited to, panic attacks, muscle spasms, anxiety, and seizures. In one aspect, the present invention relates to a fast-acting, clonazepam composition for transnasal administration that can be used for the treatment of seizure clusters.Type: ApplicationFiled: August 27, 2007Publication date: March 20, 2008Applicant: Jazz PharmaceuticalsInventors: Gene Jamieson, Michael Des Jardin, Clark Allphin
-
Publication number: 20080004329Abstract: The present invention comprises compositions for pharmaceutical drug delivery of an indolone (e.g., ropinirole), or a pharmaceutically acceptable salt thereof. The composition may, for example, be a gel suitable for transdermal application. The compositions of the present invention typically comprise a hydroalcoholic vehicle, one or more antioxidant, and one or more buffering agent, wherein the pH of the gel is usually between about pH 7 and about pH 9. The compositions may include further components, for example, the hydroalcoholic vehicle may further comprise additional solvent(s), antioxidant(s), cosolvent(s), penetration enhancer(s), buffering agent(s), and/or gelling agent(s). The compositions may be used for the treatment of a variety of neurological disorders.Type: ApplicationFiled: June 26, 2007Publication date: January 3, 2008Applicant: Jazz PharmaceuticalsInventors: Gene Jamieson, Dario Norberto Carrara, Arnaud Grenier
-
Publication number: 20060240097Abstract: Described here are TRPV1 agonist compounds and their methods of synthesis and use. In addition to specifically identified compounds, capsaicin prodrugs, gemini dimers, and mutual prodrugs are also described. Formulations of the TRPV1 agonist compounds may be in the form of a liquid, tablets, capsules, gel, cream, emulsion, a patch, or the like. Methods for treating medical conditions using the compounds, compositions, or prodrugs described, are also provided.Type: ApplicationFiled: April 25, 2006Publication date: October 26, 2006Inventors: Gene Jamieson, Naweed Muhammad, Keith Bley
-
Publication number: 20060233901Abstract: Oils of capsaicinoids and methods of making and using them are described. In some variations, the oils of capsaicinoids comprise at least 40% w/w capsaicinoid and a solvent capable of solubilizing the capsaicinoid, wherein the oil of capsaicinoid is substantially free of capsaicinoid crystals or capsaicinoid precipitates. In other variations, the oils of capsaicinoids consist essentially of at least 40% w/w capsaicinoid and a solvent capable of solubilizing the capsaicinoid. The solvent may be a semi-volatile solvent, a non-volatile solvent, or a volatile solvent, and the oil may comprise at least 50% w/w capsaicinoid, 60% w/w capsaicinoid, 70% w/w capsaicinoid, 80% w/w capsaicinoid, 90% w/w capsaicinoid, or 95% w/w capsaicinoid. The oil of capsaicinoid may also include a crystallization inhibitor.Type: ApplicationFiled: March 31, 2006Publication date: October 19, 2006Inventors: Gene Jamieson, Naweed Muhammad, Keith Bley
-
Publication number: 20060204563Abstract: The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleaning composition, e.g., a composition in which capsaicin is soluble.Type: ApplicationFiled: May 15, 2006Publication date: September 14, 2006Inventors: Arturo Angel, Larry Litle, Keith Bley, Allan Wilcox, Gene Jamieson, Naweed Muhammad
-
Publication number: 20060204561Abstract: Described here are drug delivery devices including an occlusive backing layer and a drug depot containing a TRPV1 agonist and a non-hydrophilic solvent. The drug depot may take various forms, such as an adhesive polymeric matrix, liquid reservoir, or microreservoir droplets. Methods of making and using the drug delivery devices are also described.Type: ApplicationFiled: February 14, 2006Publication date: September 14, 2006Inventors: Naweed Muhammad, Gene Jamieson, Keith Bley
-
Publication number: 20060204564Abstract: The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble.Type: ApplicationFiled: May 15, 2006Publication date: September 14, 2006Inventors: Arturo Angel, Larry Litle, Keith Bley, Allan Wilcox, Gene Jamieson, Naweed Muhammad
-
Publication number: 20050090557Abstract: Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions are also provided.Type: ApplicationFiled: April 12, 2004Publication date: April 28, 2005Inventors: Naweed Muhammad, Gene Jamieson, Keith Bley, Sanjay Chanda
-
Publication number: 20020022743Abstract: Solid aryl sulfonates are purified by preferentially dissolving impurities into an aqueous liquid phase.Type: ApplicationFiled: January 5, 2001Publication date: February 21, 2002Inventors: Sergei Pouhov, Gene Jamieson, John Vajda, Henry Kruk, John McGinley
-
Patent number: 5155224Abstract: The process of this invention for preparing Mn(II) chelate comprises forming the Mn(II) chelate by mixing manganese (II) oxide (insoluble) with an aqueous suspension comprising a molar equivalent or molar excess of the insoluble protonated chelating compound at a temperature of from 20.degree.to 50.degree. C. When the reaction is carried out with a protonated chelating agent in the absence of base, a precipitate of the protonated Mn(II) chelate is formed. A low osmolarity MN(II) chelate solution can be formed from the precipitates by dissolving them in an aqueous solution of base. When the initial chelate forming reaction is carried out in a solution containing a molar equivalent or excess of sodium hydroxide, a low osmolarity solution of the Mn(II) chelate is directly formed with most chelating agents. Preferred chelating compounds for this process include DPDP, DTPA, DCTA, EDTP, DOTA, DOXA, DO3A and EDTA.Type: GrantFiled: June 23, 1989Date of Patent: October 13, 1992Assignee: Salutar, Inc.Inventors: Scott M. Rocklage, William P. Cacheris, Gene Jamieson
-
Patent number: 4978763Abstract: The process of this invention for preparing Mn(II) chelate comprises forming the Mn(II) chelate by mixing manganese(II) oxide (insoluble) with an aqueous suspension comprising a molar equivalent or molar excess of the insoluble protonated chelating compound at a temperature of from 20.degree. to 50.degree. C. When the reaction is carried out with a protonated chelating agent in the absence of base, a precipitate of the protonated Mn(II) chelate is formed. A low osmolarity Mn(II) chelate solution can be formed from the precipitates by dissolving them in an aqueous solution of base. When the initial chelate forming reaction is carried out in a solution containing a molar equivalent or excess of sodium hydroxide, a low osmolarity solution of the Mn(II) chelate is directly formed with most chelating agents. Preferred chelating compounds for this process include DPDP, DTPA, DCTA, EDTP, DOTA, DOXA, DO3A and EDTA.Type: GrantFiled: June 23, 1989Date of Patent: December 18, 1990Assignee: Salutar, Inc.Inventors: Scott M. Rocklage, William P. Cacheris, Gene Jamieson
-
Patent number: 4889931Abstract: The process of this invention for preparing Mn(II) chelate comprises forming the Mn(II) chelate by mixing manganese(II) oxide (insoluble) with an aqueous suspension comprising a molar equivalent or molar excess of the insoluble protonated chelating compound at a temperature of from 20.degree. to 50.degree. C. When the reaction is carried out with a protonated chelating agent in the absence of base, a precipitate of the protonated Mn(II) chelate is formed. A low osmolarity Mn(II) chelate solution can be formed from the precipitates by dissolving them in an aqueous solution of base. When the initial chelate forming reaction is carried out in a solution containing a molar equivalent or excess of sodium hydroxide, a low osmolarity solution of the Mn(II) chelate is directly formed with most chelating agents. Preferred chelating compounds for this process include DPDP, DTPA, DCTA, EDTP, DOTA, DOXA, DO3A and EDTA.Type: GrantFiled: September 27, 1988Date of Patent: December 26, 1989Assignee: Salutar, Inc.Inventors: Scott M. Rocklage, William P. Cacheris, Gene Jamieson